GID BIO
Colorado-based medical organization pioneering cellular therapy for knee osteoarthritis treatment.
Founded
2008Colorado-based medical organization pioneering cellular therapy for knee osteoarthritis treatment.
Founded in Louisville, Colorado, GID BIO is a medical organization dedicated to pioneering cellular therapy for the treatment of knee osteoarthritis. Their core mission is to alleviate pain and improve function for patients suffering from this condition. GID BIO's primary product is their SVF-2 technology, which harnesses the body's natural healing processes to deliver effective cellular therapy. The company is currently advancing through a pivotal Phase III clinical trial, focusing on a market that seeks innovative solutions for chronic joint pain.
Notable figures associated with GID BIO include a team of experienced medical professionals and researchers committed to advancing cellular therapy. The organization has garnered attention from investors interested in groundbreaking medical technologies. Key achievements include progressing to Phase III trials, indicating significant potential for regulatory approval and market entry. GID BIO's work has the potential to revolutionize treatment for knee osteoarthritis, offering a promising alternative to traditional pain management and surgical interventions.
Companies similar to GID BIO include TeVido BioDevices, Greyledge Technologies, Sarcio and Spheringenics.
GID BIO was founded in 2008.
GID BIO's headquarters is located in Louisville, CO, US.
GID BIO's most recent funding round was for $250k (USD) in August 2020.
As of Aug 18, 2020, GID BIO has disclosed funding of $7.6M (USD). Undisclosed round amounts are excluded.
GID BIO has 8 employees as of Feb 5, 2024.
